Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 tumor-agnostic olaparib monotherapy study in advanced HRR-mutated or HRD-positive solid tumors
MOH_2022-07-17_003690Phase 2Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olaparib in Nonhematologic neoplasms and cancer, sponsored by Merck & Co. Started Oct 2018; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on MOH_2022-07-17_003690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-07-17_003690.